New pharma payment rules a “breach of privacy”

A senior Queensland clinician has criticised, as a "breach of privacy", rules coming into force on Thursday that pave the way for the disclosure of payments between pharmaceutical companies and doctors.

Associate Professor Michael d'Emden, director of endocrinology at Queensland Health, says disclosures should be restricted to a professional level, such as reporting conflicts of interest in submissions to government bodies.